Suggested remit: To appraise the clinical and cost effectiveness of venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor
Please note that following on from information provided to NICE by the company in March 2024, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 4040
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 April 2025 | Discontinued. Please note that following on from information provided to NICE by the company in March 2024, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 March 2024 | Suspended. Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 11 July 2023 | Note - Note added to the project documents |
| 10 February 2023 | Note added to the project documents |
| 18 January 2023 | In progress. Scoping commenced |
| 28 November 2022 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual